Sucker, Antje
Zhao, Fang
Pieper, Natalia
Heeke, Christina
Maltaner, Raffaela
Stadtler, Nadine
Real, Birgit
Bielefeld, Nicola
Howe, Sebastian
Weide, Benjamin
Gutzmer, Ralf
Utikal, Jochen
Loquai, Carmen
Gogas, Helen
Klein-Hitpass, Ludger
Zeschnigk, Michael
Westendorf, Astrid M.
Trilling, Mirko
Horn, Susanne
Schilling, Bastian
Schadendorf, Dirk
Griewank, Klaus G.
Paschen, Annette
Article History
Received: 7 September 2016
Accepted: 29 March 2017
First Online: 31 May 2017
Competing interests
: B.W.: grants from Merck/MSD, Bristol Myers Squibb, personal fees from Philogen, Roche. J.U.: advisory boards and on speakerŕs bureaus of Amgen, BMS, GSK, MSD, Novartis, and Roche. R.G.: research support from Novartis, Pfizer, Johnson&Johnson; honoraia for lectures from Roche Pharma, Bristol-MyersSquibb, GlaxoSmithKline, Novartis, Merck Serono, MSD, Almirall-Hermal, Amgen, Galderma, Janssen, Boehringer Ingelheim; paid advisory role for Roche Pharma, Bristol-MyersSquibb, GlaxoSmithKline, Novartis, MSD, Almirall-Hermal, LEO, Amgen, Pfizer. C.L.: Advisory/Consultant or speakers fee from BMS, Roche, Amgen, Novartis, Pierre Fabre, Biontech, MSD. B.S.: advisory board or honoraria from Novartis, Roche, Bristol-Myers Squibb and MSD Sharp & Dohme, research funding from Bristol-Myers Squibb and MSD Sharp & Dohme, travel support from Novartis, Roche, Bristol-Myers Squibb and AMGEN. D.S.: advisory board or honoraria from Roche, Genentech, Novartis, Amgen, GlaxoSmithKline, Bristol-Myers Squibb, Boehringer Ingelheim, and Merck Sharp & Dohme. All other authors declare no competing financial interests.